TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05236530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 2 mg (1 mL of 2 mg/mL oral solution) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Repaglinide 0.5 mg (1 x 0.5 mg tablet) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dextromethorphan 15 mg (10 mL of 7.5 mg/5 mL syrup) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg (1 x 500 mg tablet) administered as a single dose in a 4-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaplacide
Description: Ganaplacide 400 mg (4 x 100 mg tablets) administered q.d. in Period 2 on Days 1 - 3, with the 4-probe cocktail co administered on the morning of Day 3.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lumefantrine
Description: Lumefantrine 960 mg (4 x 240 mg sachets) administered q.d. on Days 1 - 3, with the 4-probe cocktail (as a single dose) co administered on the morning of Day 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 5 mg (1 x 5 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir 50 mg (1 x 50 mg tablet) administered as a single dose in a 2-probe cocktail in the morning in Period 1 on Day 1 and in Period 2 on Day 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaplacide
Description: Ganaplacide 400 mg (4 x 100 mg tablets) administered q.d. in Period 2 on Days 1 - 3, with the 2-probe cocktail co administered on the morning of Day 3.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lumefantrine
Description: Lumefantrine 960 mg (4 x 240 mg sachets) administered q.d. on Days 1 - 3, with the 4-probe cocktail (as a single dose) co administered on the morning of Day 3.
Study: NCT06384924

Intervention type: DEVICE
Intervention: Raman Spectroscopy handheld probe (EmVision, FL, USA)
Description: The probe is approximately the size of a pen or pencil. The handheld probe is connected to the laser source using a cable. The probe is placed in light contact with the skin. The features of the laser light after it bounces off the skin is collected. This measurement can allow us to see tissue characteristics. This is a single session that will take approximately 15 minutes.

Intervention type: DEVICE
Intervention: Raman Spectroscopy laser source (Hubner Photonics Inc, CA, USA)
Description: This light source will create the laser light that will pass through the cable and through the handheld probe onto the skin.
Study: NCT05601336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 5 MG
Description: SGLT2 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride 1000 MG
Description: metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin/Metformin
Description: SGLT2 inhibitor and metformin HCl extended-release
Study: NCT05052905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LibraVR
Description: LibraVR is a standalone VR-based rehabilitation software for use in physiotherapy. It is designed to work with standard off-the-shelf hardware that is tested and approved for use in conjunction with the software.~LibraVR system consists of the software (LibraVR Clinic) running on a PC (database of patients, creation of protocols, uploading protocols to mobile), and the LibraVR Mobile APP that runs on commercial mobile smartphones embedded in a lightweight cardboard or plastic VR viewer that the child wears as they would eyeglasses. The software displays a range of immersive VR exercises.
Study: NCT05551416

Intervention type: OTHER
Intervention: Identification of risk factors
Description: Demographics, life habits and risk factors studies

Intervention type: OTHER
Intervention: Identification of risk factors
Description: Demographics, life habits and risk factors studies

Intervention type: OTHER
Intervention: Identification of risk factors
Description: Demographics, life habits and risk factors studies

Intervention type: OTHER
Intervention: Identification of risk factors
Description: Demographics, life habits and risk factors studies

Intervention type: OTHER
Intervention: Characterization of premalignant gastric lesions
Description: Identification and characterization of premalignant gastric lesions through high definition endoscopic study. Concordance between endoscopic and histological classifications

Intervention type: OTHER
Intervention: Characterization of premalignant gastric lesions
Description: Identification and characterization of premalignant gastric lesions through high definition endoscopic study. Concordance between endoscopic and histological classifications

Intervention type: OTHER
Intervention: Identification of biomarkers
Description: Multiomic studies

Intervention type: OTHER
Intervention: Identification of biomarkers
Description: Multiomic studies

Intervention type: OTHER
Intervention: Identification of biomarkers
Description: Multiomic studies

Intervention type: OTHER
Intervention: Identification of biomarkers
Description: Multiomic studies

Intervention type: OTHER
Intervention: Identification of gastric cancer hereditary predisposition
Description: Genomic studies for the identification of individuals with hereditary GC predisposition
Study: NCT05962697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SA controller
Description: Novel controller to be tested

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TA controller
Description: original controller to be tested

Intervention type: OTHER
Group type: OTHER
Intervention: SA controller early testing
Description: Novel controller to be tested early testing
Study: NCT05883982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: I-PRF injection
Description: Intra-articular I-PRF injection to temporomandibular joint cavity
Study: NCT06351046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfullness Based Stress Reduction Program
Description: Online group class/week for eight consecutive weeks with 8 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based Pain Self-management program
Description: The VRPS has a variety of modules that can be used for pain management. For this project we have selected relaxation, mindful escapes, pain distraction games, and dynamic breathing modules. All modules were designed to minimize triggers of emotional distress or cybersickness.
Study: NCT05230901

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Patients with CMR-derived ECV% levels ≥25.9% will be treated with standard of care according to current guidelines (Control group).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Patients with CMR-derived ECV% levels ≥25.9% will be treated with standard of care according to current guidelines (Control group).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Patients with CMR-derived ECV% levels ≥25.9% will be treated with standard of care according to current guidelines (Control group).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 25mg
Description: Patients with CMR-derived ECV% levels ≥25.9% in Arm Spironolactone will receive spironolactone 25 mg/d in addition to standard of care medication .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 25mg
Description: Patients with CMR-derived ECV% levels ≥25.9% in Arm Spironolactone will receive spironolactone 25 mg/d in addition to standard of care medication .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydralazine
Description: Patients with CMR-derived ECV% levels ≥25.9% in arm Spironolactone + Dihydralazine will receive spironolactone 25 mg/d + dihydralazine (2x12.5 mg/d p.o. in slow acethylators, and 2x25mg/d p.o. in fast acethylators, confirmed by genetic testing)
Study: NCT06557681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Treadmill Training Group (VTT)
Description: The Virtual Reality-Treadmill Training Group (VTT) will consist of 15 participants who will undergo 12 training sessions over 6 weeks, with each session occurring twice a week. Each session will include 30 minutes of conventional rehabilitation therapy followed by an additional 30 minutes of virtual reality-treadmill training. The sequence of these therapies can vary with each session. The virtual reality-treadmill training, conducted under the supervision of a therapist, will focus on five key components: precision stepping, obstacle negotiation, direction of progression, precision acceleration, and walking velocity. Evaluations of walking and balance abilities will be conducted before and after the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy Group (CT)
Description: The Conventional Therapy Group (CT) will consist of 15 participants who will undergo 12 training sessions over 6 weeks, with each session occurring twice a week. Each session will include 30 minutes of conventional rehabilitation therapy, aimed at improving walking and balance functions. The therapy will be administered by a therapist and may include exercises focused on muscle strength increase, gait training for step length and walking speed improvement, and balance training. Evaluations of walking and balance abilities will be conducted before and after the intervention.
Study: NCT06412003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based balance training
Description: This is a family member supported home-based balance training program designed for community-dwelling people with MS to improve balance and walking abilities as well as cognitive functions. The intervention program aims to have participants with MS reach high-intensity balance tasks during the program. A bi-weekly two-on-one, semi-structured, video-chat session with participants and their exercise supporter and research team will be conducted using videoconferencing techniques (e.g., Zoom, Skype, or Facetime).
Study: NCT04712461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUPPORTS
Description: The SUPPORTS implementation model will be developed and refined based on community feedback. It will likely include a combination of strategies demonstrated to reduce burnout and secondary traumatic stress in the occupational health literature, such as psychoeducation about burnout, mindfulness training, or changes in scheduling or the physical environment. As the most effective interventions have been shown to involve an integration of both individual- and organization-directed strategies supporting each other, SUPPORTS will aim to include both. For example, the model may include provider-directed strategies such as group peer consultation meetings, and organizational-directed strategies such as increasing communication and providers' involvement in organizational decisions. Through this approach, SUPPORTS will aim to target therapist burnout and turnover at the provider and organizational level.
Study: NCT05207501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform 3 times a week for 4 weeks a moderate intensity interval training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform 3 times a week for 4 weeks a moderate intensity interval training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will perform 3 times a week for 4 weeks a moderate intensity interval training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants will perform 3 times a week for 4 weeks a moderate intensity interval training.
Study: NCT04909723

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NOV-001
Description: NOV-001 is an investigational combination product composed of NB1000S, a recombinant live biotherapeutic product, and NB2000P, a botanically derived polysaccharide.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NOV-001
Description: NOV-001 is an investigational combination product composed of NB1000S, a recombinant live biotherapeutic product, and NB2000P, a botanically derived polysaccharide.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NOV-001
Description: NOV-001 is an investigational combination product composed of NB1000S, a recombinant live biotherapeutic product, and NB2000P, a botanically derived polysaccharide.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NOV-001
Description: NOV-001 is an investigational combination product composed of NB1000S, a recombinant live biotherapeutic product, and NB2000P, a botanically derived polysaccharide.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB1000S
Description: A recombinant live biotherapeutic product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB2000P
Description: A botanically derived polysaccharide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04796415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the DEMA-Pro intervention
Description: Trained DEMA-Pro coaches will deliver six weekly, 1-hour telephone sessions. The first session is an orientation to the DEMA-Pro intervention and development of the initial Weekly Activity Plan based on the patient's self-identified meaningful activity. Over the next five weekly sessions, the coach uses problem-solving strategies to facilitate dyad collaboration to mutually identify meaningful activities and make a realist plan to achieve the patient-identified meaning activity goals. In each session, the patient and caregiver also select, review, and discuss one of six topics in the Self-Management Toolkit (e.g., planning meaningful activities; learning strategies for living with subjective cognitive impairment; finding resources, planning for the future).
Study: NCT05531253

Intervention type: OTHER
Intervention: Data collection using the Optical Gas Analyser
Description: To allow the OGA to acquire certain physiological data during the study it will be necessary to slightly vary the tension of oxygen and carbon dioxide for short periods. The changes involved will be of a lesser magnitude than those often seen due to natural variation over time in critically ill patients. The FiO2 will be increased by around 20% from baseline for several minutes; this is a far more modest increase than is seen with the practice of pre-oxygenation - a transitory increase in fraction of inspired oxygen ( FiO2) to 100% - performed regularly in ICU patients to make certain routine interventions safer. The end-tidal CO2 level will also briefly (1-2 min) be altered by around 1 kPa by transient adjustment of the ventilator settings.
Study: NCT06262867

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready. Set. Food! Stage 1 Mix ins
Description: These supplements contain cow's milk, eggs, and peanuts.
Study: NCT05303714

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX and PIPAC
Description: A minilaparotomy is performed in the midline. A 5 mm balloon trocar is inserted under finger protection in the right side and the fascia of the minilaparotomy is closed. The abdomen is insufflated with CO2 and a second 10-12mm trocar is introduced under videoscope control in upper left side. Ascites volume is documented and removed sending a sample for cytological examination, an accurate exploratory laparoscopy is performed, possibly placing an additional 5 or 10-12 mmHg trocar, the Peritoneal Cancer Index is calculated. Multiple biopsies are performed in different abdominal quadrants. A nebulizer CAPNOPEN© is inserted into the upper left side trocar and fixed with a 45° angle. The drugs (Cisplatin 10.5 mg/m2 body surface in 150 mL; Doxorubicin 2.1 mg/m2 body surface in 50 mL) are then injected through remote control with a flow rate of 0.7 mL/sec with a pressure of 200 psi. After an aerosol exposure phase of 30min, the aerosol is evacuated via a closed waste system.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FOLFOX and PIPAC
Description: A minilaparotomy is performed in the midline. A 5 mm balloon trocar is inserted under finger protection in the right side and the fascia of the minilaparotomy is closed. The abdomen is insufflated with CO2 and a second 10-12mm trocar is introduced under videoscope control in upper left side. Ascites volume is documented and removed sending a sample for cytological examination, an accurate exploratory laparoscopy is performed, possibly placing an additional 5 or 10-12 mmHg trocar, the Peritoneal Cancer Index is calculated. Multiple biopsies are performed in different abdominal quadrants. A nebulizer CAPNOPEN© is inserted into the upper left side trocar and fixed with a 45° angle. The drugs (Cisplatin 10.5 mg/m2 body surface in 150 mL; Doxorubicin 2.1 mg/m2 body surface in 50 mL) are then injected through remote control with a flow rate of 0.7 mL/sec with a pressure of 200 psi. After an aerosol exposure phase of 30min, the aerosol is evacuated via a closed waste system.
Study: NCT06268223

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chewing Exercise Training
Description: All groups will implement the Functional Chewing Exercise, consisting of 5 sets per day, 5 days a week, for 12 weeks. Additionally, the study group will participate in an Action Observation Training program, conducted via telerehabilitation, involving 1 set per day, 3 days a week, for 12 weeks, with the guidance of a physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing Exercise Training
Description: All groups will implement the Functional Chewing Exercise, consisting of 5 sets per day, 5 days a week, for 12 weeks. Additionally, the study group will participate in an Action Observation Training program, conducted via telerehabilitation, involving 1 set per day, 3 days a week, for 12 weeks, with the guidance of a physiotherapist.
Study: NCT05887492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG260
Description: CoREST inhibitor, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG260
Description: CoREST inhibitor, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG260
Description: CoREST inhibitor, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG260
Description: CoREST inhibitor, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, an anti-PD-1 antibody, administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, an anti-PD-1 antibody, administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, an anti-PD-1 antibody, administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, an anti-PD-1 antibody, administered intravenously
Study: NCT05612321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum application
Description: vacuum-assisted delivery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum application
Description: vacuum-assisted delivery
Study: NCT06134388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: Sulfasalazine is an anti-inflammatory drug that is indicated for treatment of ulcerative colitis and rheumatoid arthritis.
Study: NCT05255107

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution
Description: Standard Of Care: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion. Following SOC, for subjects randomized to the experimental arm, riboflavin will be administered (1 drop every 2 min for 40 min with PESCHKE-L solution \[0.23%\], or longer as needed to assure adequate corneal penetration). Then the eye will be aligned under the PXL Platinum 330 light (the treatment plane will be at the correct working distance from the PXL Platinum 330 beam aperture when the border of the projected beam is in sharp focus). The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of Care Therapy + Sham CXL + Artificial Tears
Description: Standard Of Care: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion. Following SOC, for subjects randomized to the Sham comparator group, artificial tears (1 drop every 2 min for 40 min) will be administered. After instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min, during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
Study: NCT00988182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: whey protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: whey protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: whey protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: whey protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water control
Study: NCT04832035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coordinated and peer supported mental health care
Description: Health services, coordination of services, method to support utilization

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard psychotherapeutic care in the public healthcare system
Description: Psychotherapeutic services that are financed by the public health insurance system.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: standard psychotherapeutic care in the public healthcare system
Description: Psychotherapeutic services that are financed by the public health insurance system.